Encouraging data for ViiV’s long-acting, two-drug HIV therapy

ViiV Healthcare has unveiled encouraging mid-stage data backing a long-acting formulation of its two-drug regimen cabotegravir and rilpivirine for the treatment of HIV.Original Article